INS and Insulin resistance: Recent studies have suggested that short-term intensive insulin therapy, with continuous subcutaneous insulin infusion (CSII) potentially being the best current therapeutic option [2, 3], can rapidly relieve newly diagnosed T2DM patients of high glucose toxicity, ameliorate the state of insulin resistance, and restore islet β-cell function [4, 5].